Promising therapeutic targets of endometriosis obtained from microRNA studies

Kaei Nasu, Yoko Aoyagi, Ruofei Zhu, Mamiko Okamoto, Kentaro Kai, Yasushi Kawano
Medical molecular morphology · 2021 · vol. 55(2) , pp. 85–90 · doi:10.1007/s00795-021-00308-3 · PMID:34846581 · W3215481707
review OA: green CC0 ⤵ 6 in-corpus citations
🔓 Open OA copy Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-12 ⓘ

Nine overexpressed microRNAs were identified as inducing endometriosis characteristics, with their downstream target molecules proposed as promising therapeutic targets.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text ⓘ

This paper reviews prior studies on aberrantly expressed microRNAs (miRNAs) in endometriosis, identifying nine miRNAs reported as overexpressed and examining their effects in endometriotic tissues and cells. The authors report that these overexpressed miRNAs promote endometriosis-associated phenotypes, including inhibition of apoptosis and decidualization, and increased fibrogenesis, invasion, migration, proliferation, attachment to extracellular matrix, inflammation, and angiogenesis. Based on the downstream target molecules of these miRNAs (e.g., early growth response protein-1, ERK, matrix metallopeptidase 1, STAT3, COX-2, PI3K/AKT, mTOR, and VEGF-A), the paper proposes these molecules as promising therapeutic targets. It does not present new experimental data and instead synthesizes literature, with the limitation that complex miRNA mechanisms and clinical treatment relationships are inferred rather than tested within this review. This paper is centrally about endometriosis — it synthesizes endometriosis-associated overexpressed miRNAs and their downstream targets as candidate therapeutic targets.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 5,489 characters · extracted from oa-html · click to expand
WEKO3 アイテム Promising therapeutic targets of endometriosis obtained from microRNA studies http://hdl.handle.net/10559/16994 http://hdl.handle.net/10559/16994efdf5bbf-7896-4094-bd43-5650275cd07c | 名前 / ファイル | ライセンス | アクション | |---|---|---| | promising_therapeutic_targets_of_endometriosis_obtained_from_microrna_studies.pdf | | | | table1.pdf | | | | figure1.jpg | | | アイテムタイプ | デフォルトアイテムタイプ（フル）(1) | ||||||||||||||||||||||||||| |---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---| | 公開日 | 2023-06-01 | ||||||||||||||||||||||||||| | タイトル | |||||||||||||||||||||||||||| | タイトル | Promising therapeutic targets of endometriosis obtained from microRNA studies | ||||||||||||||||||||||||||| | 言語 | en | ||||||||||||||||||||||||||| | 作成者 | Nasu, Kaei × Nasu, Kaei × Aoyagi, Yoko × Zhu, Ruofei × Okamoto, Mamiko × Kai, Kentaro × Kawano, Yasushi | ||||||||||||||||||||||||||| | アクセス権 | |||||||||||||||||||||||||||| | アクセス権 | open access | ||||||||||||||||||||||||||| | アクセス権URI | http://purl.org/coar/access_right/c_abf2 | ||||||||||||||||||||||||||| | 権利情報 | |||||||||||||||||||||||||||| | 権利情報 | (c) 2021, The Author(s) under exclusive licence to The Japanese Society for Clinical Molecular Morphology.This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature's AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s00795-021-00308-3 | ||||||||||||||||||||||||||| | 言語 | en | ||||||||||||||||||||||||||| | 主題 | |||||||||||||||||||||||||||| | 言語 | en | ||||||||||||||||||||||||||| | 主題 | endometriosis | ||||||||||||||||||||||||||| | 主題 | |||||||||||||||||||||||||||| | 言語 | en | ||||||||||||||||||||||||||| | 主題 | epigenetics | ||||||||||||||||||||||||||| | 主題 | |||||||||||||||||||||||||||| | 言語 | en | ||||||||||||||||||||||||||| | 主題 | microRNA (miRNA) | ||||||||||||||||||||||||||| | 主題 | |||||||||||||||||||||||||||| | 言語 | en | ||||||||||||||||||||||||||| | 主題 | pathogenesis | ||||||||||||||||||||||||||| | 内容記述 | |||||||||||||||||||||||||||| | 内容記述 | Endometriosis is a benign tumor that affect 6–10% women of reproductive age. To date, it is suggested that the aberrant microRNA (miRNA) expressions play important roles in the pathogenesis of endometriosis. Reviewing the literature, we found nine overexpressed miRNAs, which were thoroughly investigated in the context of endometriotic tissues and cells. Most of the overexpressed miRNAs induced endometriosis-specific characteristics including inhibition of apoptosis and decidualization, upregulation of fibrogenesis, invasion, migration, cell proliferation, attachment to extracellular matrix, inflammation, and angiogenesis in the endometriotic cells. Then, we found that the downstream target molecules of these miRNAs, such as early growth response protein-1, extracellular signal-regulated kinase, matrix metallopeptidase 1, signal transducer and activator of transcription 3, cyclooxygenase-2, phosphoinositide 3-kinase, AKT, mammalian target of rapamycin, and vascular endothelial growth factor-A are promising for the therapeutic targets of endometriosis. Recent findings suggest that complex molecular mechanisms leading to development and progression of endometriosis by miRNAs may exist in endometriosis. The meticulous balance between tumorigenic miRNAs and tumoristatic miRNAs may destine the natural course and response to the surgical, medical, and hormonal treatments of this disease. Further investigations into endometriosis-associated miRNAs may elucidate the pathogenesis of endometriosis and help to develop novel therapeutics. | ||||||||||||||||||||||||||| | 言語 | en | ||||||||||||||||||||||||||| | 出版者 | |||||||||||||||||||||||||||| | 出版者 | Springer Nature | ||||||||||||||||||||||||||| | 言語 | en | ||||||||||||||||||||||||||| | 日付 | |||||||||||||||||||||||||||| | 日付 | 2022-06-01 | ||||||||||||||||||||||||||| | 日付タイプ | Issued | ||||||||||||||||||||||||||| | 言語 | |||||||||||||||||||||||||||| | 言語 | eng | ||||||||||||||||||||||||||| | 資源タイプ | |||||||||||||||||||||||||||| | 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | ||||||||||||||||||||||||||| | 資源タイプ | journal article | ||||||||||||||||||||||||||| | 出版タイプ | |||||||||||||||||||||||||||| | 出版タイプ | AM | ||||||||||||||||||||||||||| | 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | ||||||||||||||||||||||||||| | 識別子 | |||||||||||||||||||||||||||| | 識別子 | http://hdl.handle.net/10559/16994 | ||||||||||||||||||||||||||| | 識別子タイプ | HDL | ||||||||||||||||||||||||||| | 関連情報 | |||||||||||||||||||||||||||| | 関連タイプ | isVersionOf | ||||||||||||||||||||||||||| | 識別子タイプ | DOI | ||||||||||||||||||||||||||| | 関連識別子 | https://doi.org/10.1007/s00795-021-00308-3 | ||||||||||||||||||||||||||| | 収録物識別子 | |||||||||||||||||||||||||||| | 収録物識別子タイプ | ISSN | ||||||||||||||||||||||||||| | 収録物識別子 | 1860-1480 | ||||||||||||||||||||||||||| | 収録物名 | |||||||||||||||||||||||||||| | 収録物名 | Medical Molecular Morphology | ||||||||||||||||||||||||||| | 言語 | en | ||||||||||||||||||||||||||| | 巻 | |||||||||||||||||||||||||||| | 巻 | 55 | ||||||||||||||||||||||||||| | 号 | |||||||||||||||||||||||||||| | 号 | 2 | ||||||||||||||||||||||||||| | 開始ページ | |||||||||||||||||||||||||||| | 開始ページ | 85 | ||||||||||||||||||||||||||| | 終了ページ | |||||||||||||||||||||||||||| | 終了ページ | 90 |

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Endometriosis Endometriosis Endometriosis Endometriosis MicroRNAs MicroRNAs MicroRNAs Cell Proliferation Cell Proliferation Endometrium Endometrium Female Humans Phosphatidylinositol 3-Kinases Phosphatidylinositol 3-Kinases Phosphatidylinositol 3-Kinases Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor A

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (37)

Cited by (6)

Source provenance

europepmc
last seen: 2026-06-14T06:08:20.186862+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:24:08.918168+00:00
License: CC0 · commercial use OK